Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.

Nishina K, Piao W, Yoshida-Tanaka K, Sujino Y, Nishina T, Yamamoto T, Nitta K, Yoshioka K, Kuwahara H, Yasuhara H, Baba T, Ono F, Miyata K, Miyake K, Seth PP, Low A, Yoshida M, Bennett CF, Kataoka K, Mizusawa H, Obika S, Yokota T.

Nat Commun. 2015 Aug 10;6:7969. doi: 10.1038/ncomms8969.

2.

Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.

Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, Weber M, Lazari O, Perez-Tosar L, Fancy SA, Lapthorn C, Green MX, Evans S, Selby M, Jones G, Jones L, Kearney S, Mechiche H, Gikunju D, Subramanian R, Uhlmann E, Jurk M, Vollmer J, Ciaramella G, Yeadon M.

Mol Ther. 2011 Dec;19(12):2163-8. doi: 10.1038/mt.2011.206. Epub 2011 Oct 4.

3.

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.

Nishina T, Numata J, Nishina K, Yoshida-Tanaka K, Nitta K, Piao W, Iwata R, Ito S, Kuwahara H, Wada T, Mizusawa H, Yokota T.

Mol Ther Nucleic Acids. 2015 Jan 13;4:e220. doi: 10.1038/mtna.2014.72.

4.

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.

Straarup EM, Fisker N, Hedtjärn M, Lindholm MW, Rosenbohm C, Aarup V, Hansen HF, Ørum H, Hansen JB, Koch T.

Nucleic Acids Res. 2010 Nov;38(20):7100-11. doi: 10.1093/nar/gkq457. Epub 2010 Jul 8.

5.

Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.

Watanabe A, Nakajima M, Kasuya T, Onishi R, Kitade N, Mayumi K, Ikehara T, Kugimiya A.

J Pharmacol Exp Ther. 2016 May;357(2):320-30. doi: 10.1124/jpet.115.230300. Epub 2016 Feb 23.

PMID:
26907624
6.

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S, Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE, Seth PP.

Nucleic Acids Res. 2014 Jul;42(13):8796-807. doi: 10.1093/nar/gku531. Epub 2014 Jul 3.

7.

Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol.

Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T.

Mol Ther. 2008 Apr;16(4):734-40. doi: 10.1038/mt.2008.14. Epub 2008 Feb 12.

8.

Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.

Subramanian RR, Wysk MA, Ogilvie KM, Bhat A, Kuang B, Rockel TD, Weber M, Uhlmann E, Krieg AM.

Nucleic Acids Res. 2015 Oct 30;43(19):9123-32. doi: 10.1093/nar/gkv992. Epub 2015 Oct 7.

9.

Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.

Yamamoto T, Sawamura M, Wada F, Harada-Shiba M, Obika S.

Bioorg Med Chem. 2016 Jan 1;24(1):26-32. doi: 10.1016/j.bmc.2015.11.036. Epub 2015 Nov 27.

PMID:
26678173
10.

Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.

Wada S, Yasuhara H, Wada F, Sawamura M, Waki R, Yamamoto T, Harada-Shiba M, Obika S.

J Control Release. 2016 Mar 28;226:57-65. doi: 10.1016/j.jconrel.2016.02.007. Epub 2016 Feb 5.

PMID:
26855051
11.

Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.

Prakash TP, Yu J, Kinberger GA, Low A, Jackson M, Rigo F, Swayze EE, Seth PP.

Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3774-3779. doi: 10.1016/j.bmcl.2018.10.011. Epub 2018 Oct 10.

PMID:
30342955
12.

Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA.

Pendergraff HM, Krishnamurthy PM, Debacker AJ, Moazami MP, Sharma VK, Niitsoo L, Yu Y, Tan YN, Haitchi HM, Watts JK.

Mol Ther Nucleic Acids. 2017 Sep 15;8:158-168. doi: 10.1016/j.omtn.2017.06.012. Epub 2017 Jun 21.

13.

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.

Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Ørum H, Elmén J, Seidah NG, Straarup EM.

PLoS One. 2010 May 17;5(5):e10682. doi: 10.1371/journal.pone.0010682.

14.

Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.

Ward AJ, Norrbom M, Chun S, Bennett CF, Rigo F.

Nucleic Acids Res. 2014 May;42(9):5871-9. doi: 10.1093/nar/gku184. Epub 2014 Mar 3.

15.

Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.

Wada F, Yamamoto T, Ueda T, Sawamura M, Wada S, Harada-Shiba M, Obika S.

Nucleic Acid Ther. 2018 Feb;28(1):50-57. doi: 10.1089/nat.2017.0698. Epub 2018 Jan 23.

PMID:
29360004
16.

Antisense oligonucleotides: from design to therapeutic application.

Chan JH, Lim S, Wong WS.

Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):533-40. Review.

PMID:
16700890
17.

Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.

Hung G, Xiao X, Peralta R, Bhattacharjee G, Murray S, Norris D, Guo S, Monia BP.

Nucleic Acid Ther. 2013 Dec;23(6):369-78. doi: 10.1089/nat.2013.0443. Epub 2013 Oct 26. Erratum in: Nucleic Acid Ther. 2014 Apr;24(2):178.

PMID:
24161045
18.

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.

Kasuya T, Hori S, Watanabe A, Nakajima M, Gahara Y, Rokushima M, Yanagimoto T, Kugimiya A.

Sci Rep. 2016 Jul 27;6:30377. doi: 10.1038/srep30377.

19.

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.

Burel SA, Hart CE, Cauntay P, Hsiao J, Machemer T, Katz M, Watt A, Bui HH, Younis H, Sabripour M, Freier SM, Hung G, Dan A, Prakash TP, Seth PP, Swayze EE, Bennett CF, Crooke ST, Henry SP.

Nucleic Acids Res. 2016 Mar 18;44(5):2093-109. doi: 10.1093/nar/gkv1210. Epub 2015 Nov 8.

20.

Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.

Shimizu R, Kitade M, Kobayashi T, Hori S, Watanabe A.

J Pharmacokinet Pharmacodyn. 2015 Feb;42(1):67-77. doi: 10.1007/s10928-014-9398-5. Epub 2014 Nov 7.

PMID:
25376372

Supplemental Content

Support Center